On July 31, 2025, Soligenix, Inc. (SNGX) announced encouraging results from the Phase 2a clinical trial of SGX-945 (dusquetide) for the treatment of Behcet's disease (BD) in which the compound demonstrated biological efficacy. This was an open-label study designed to be highly comparable to the Phase 3 trial of apremilast (Otezla ) that was the basis for marketing approval for oral ulcers in BD. Using the same primary endpoint as the Phase 3 apremilast study (area under the curve of the mean number of ulcers vs. time), after four weeks of treatment the SGX945 group had a 40% improvement relative to the placebo group from the Phase 3 apremilast study, while apremilast had a 37% improvement relative to placebo. Soligenix will be reformulating SGX945 to enable home-based treatment before embarking on a placebo-controlled Phase 2 study.
